LDL‐cholesterol · Participants with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
White population, hypertensive, SBP mmHg · White population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
White population, hypertensive, DBP mmHg · White population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, normotensive, SBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, normotensive, DBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, hypertensive, SBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Black population, hypertensive, DBP mmHg · Black population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Asian population, normotensive, SBP mmHg · Asian population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Relapse · people with multiple sclerosis
It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Omega‐3 showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with omega‐6 (low certainty).
1 finding from 1 review
Relapse · people with multiple sclerosis
Antioxidant showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Antioxidant showed no clear difference in global impression of deterioration (investigator defined global… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis
It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).
1 finding from 1 review
MRI activity ‐ not measured · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with multiple sclerosis
1 finding from 1 review
Relapse · people with multiple sclerosis
Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).
1 finding from 1 review